biostudies-literatureUnknown8(7)Blohmer JU<h4>Importance</h4>Adjuvant denosumab might improve disease-free survival in hormone receptor (HR)-positive primary breast cancer (BC). The optimal neoadjuvant nab-paclitaxel schedule in terms of efficacy and safety is unclear.<h4>Objective</h4>To determine whether adding denosumab to anthracycline/taxane-containing neoadjuvant chemotherapy (NACT) increases the pathological complete response (pCR) rate and which nab-paclitaxel schedule is more effective in the NACT setting.<h4>Design, setting, and participants</h4>The GeparX was a multicenter, prospective, open-label, phase 2b, 2 × 2 randomized clinical trial conducted by GBG and AGO-B at 38 German sites between February 2017 and March 2019. The analysis data set was locked September 4, 2020; analysis was completed November 13, 2020. PatieJAMA oncology1010-1018https://www.ebi.ac.uk/biostudies/studies/S-EPMC9121303biostudies-literatureEffect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.PMC9121303Rhiem KSeiler SHackmann JWullner MPWarm MLubbe KJackisch CPaulenz AFrank MUntch MLoibl SRenner SDenkert CKummel STesch HBuchen SHofman MFasching PASeither FKuhn CGBG and AGO-BHanusch CMahlberg RBuckner UHolms FRadosa JDecker TWeigel MHartkopf ASolbach CTome OKrabisch PThomalla JReinisch MHofmann ONoesselt TJust MStotzer OKuhn WHuober JKunz GSchneeweiss ALink TSchilling JBlohmer JUFehm TRom JJung CHeinrich BNekljudova VWimberger PEngels KSimon ESchmatloch SThill MfalseEffect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.<h4>Importance</h4>Adjuvant denosumab might improve disease-free survival in hormone receptor (HR)-positive primary breast cancer (BC). The optimal neoadjuvant nab-paclitaxel schedule in terms of efficacy and safety is unclear.<h4>Objective</h4>To determine whether adding denosumab to anthracycline/taxane-containing neoadjuvant chemotherapy (NACT) increases the pathological complete response (pCR) rate and which nab-paclitaxel schedule is more effective in the NACT setting.<h4>Design, setting, and participants</h4>The GeparX was a multicenter, prospective, open-label, phase 2b, 2 × 2 randomized clinical trial conducted by GBG and AGO-B at 38 German sites between February 2017 and March 2019. The analysis data set was locked September 4, 2020; analysis was completed November 13, 2020. Patie2022-01-01T00:00:00Z2022 Jul2026-05-09T22:31:26.849Z2024-11-07T10:25:45.848ZS-EPMC91213033558805010.1001/jamaoncol.2022.1059